Three studies presented on Dec. 9 at the American Epilepsy Society annual meeting suggest new uses for levetiracetam (Keppra). A phase IV trial found that levetiracetam is as effective and safe in a community setting as in the phase III controlled trial, supporting its use as add-on therapy for partial-onset seizures.
Another study suggests that it could be used as monotherapy and may also be effective in generalized seizures. And a third study suggests that this benefit may be extended to children younger than two years. “Levetiracetam is an important addition to the therapeutic armamentarium for epilepsy,” write Martha J. Morrell, from Columbia Prsebyterian Medical Center in New York, N.Y., and colleagues. “In the community setting, levetiracetam performance may be even greater than in clinical trials.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!